Reference | No. of assessable/ scintigraphically examined patients (disease) | Relevant exclusion criteria and cardiovascular risk factors | Follow-up period | Radiotherapy protocol | Type of isotope | Method of evaluation | Normal MPI results |
---|---|---|---|---|---|---|---|
Glanzmann et al. (62,74) | 112/100 (HD) | Obesity, hypertension, smoking, diabetes, hypercholesterolemia, history of coronary artery disease assessed; previous adriamycin-including Ct allowed; age <65 y at RT | 1–31.5 y | 30–42 Gy in 93% of cases; 1.3–2.1 Gy/fraction to anterior heart region | 99mTc-sestamibi | SPECT | 93/100 |
Gyenes et al. (66,75) | 17/12 (left-side BC) | Obesity, hypertension, smoking, diabetes, hypercholesterolemia, history of coronary artery disease assessed; age <70 y; adriamycin-including Ct in 3/17 patients | 0.7–1.9 y | Breast: 50 Gy (γ), 25 fractions; chest wall, internal mammary nodes, supraclavicular nodes, axilla: 46 Gy (β and γ), 2 Gy/fraction | 99mTc-sestamibi | SPECT | 6/12 |
Gustavsson et al. (68) | 91/90 (left- or right-side BC) | Family history of cardiac disease, smoking, hypertension, diabetes, hypercholesterolemia assessed; age <65 y; Ct (cyclophosphamide) in 59/90 patients | 10–17 y | Supraclavicular/infraclavicular: 45 Gy (γ); axilla: 48 Gy (γ); chest wall: 38 Gy (radiography); internal mammary nodes: 48 Gy (β), 1.9–2.4 Gy/fraction | 99mTc-sestamibi and 99mTc-tetrofosmin | SPECT | 84/90 |
Hojris et al. (76) | 17/16 (left-side BC) | Obesity, hypertension, diabetes, hypercholesterolemia, smoking, and family history assessed; history of heart disease not allowed; age <75 y; systemic hormonal therapy in 6/17 patients and non–adriamycin-containing Ct in 11/17 patients | 6–12.2 y | Supraclavicular/infraclavicular nodes, axilla, chest wall, internal mammary nodes: median, 50 Gy; 1.9–2.4 Gy/fraction | 99mTc-sestamibi | SPECT | 3/7 in no-RT group; 5/9 in RT group |
Hardenbergh et al. (69) | 20/20 (left-side BC) | Previous doxorubicin-containing Ct in 10/20 patients | 6 mo | Breast, chest wall: 46–50 Gy, tangential beams, upper internal mammary nodes included in tangent fields in 5/20 patients, 2 Gy/fraction | 99mTc-sestamibi | Gated SPECT | 8/20 in total group; 3/10 in Ct group; 5/10 in RT-alone group |
HD = Hodgkin’s disease; BC = breast cancer.